Published in Cardiovascular Business Week, May 2nd, 2006
For the fourth quarter, the company's net loss was $2.2 million, which included a non-cash charge of $0.6 million for previously capitalized patents costs. The net loss for 2005 resulted primarily from the continued research and development expenditures related to ongoing phase II clinical trials to study the company's product (TB4) for the treatment of chronic dermal wounds, research and development efforts related to its technology platform,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.